synlayer builds the evidence layer for clinical judgment: products that read what clinicians already have, synthesize the evidence, and cite every line.
Consider the condition first. The deciding test is not yet in the case.
Each sentence links to the passage it came from. A sentence with no source is removed before anyone sees it.
Each product serves different clinicians and is paid for by different organizations. Both run on the same engine and make the same promise.
Cense gives every physician the clinical sense of a rare-disease specialist: a ranked differential where every line is cited.
Grovera shows families and clinicians what the evidence says about each intervention, and whether this child is actually changing.
In both, the knowledge exists. It does not reach the moment of decision.
Rare to each physician, common together. Patients wait years for a name.
Many interventions for each family, hard to compare. Progress is often measured by feel.
A second product line mostly costs clinical content, not a new technology stack.
Both products are reviewed at the same two gates. A product that misses its gate does not move to the next phase.
Dates are approximate. Both products launch in the United States, in English, from a single US deployment.